{
    "nct_id": "NCT04145531",
    "official_title": "An Open-Label, Multicenter Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coli-derived Asparaginases",
    "inclusion_criteria": "1. Pediatric and adult patients with a diagnosis of ALL or LBL.\n2. Have had an allergic reaction to a long-acting E. coli-derived asparaginase OR have silent inactivation.\n3. Have 1 or more courses of E. coli-derived asparaginase remaining in his/her treatment plan.\n4. Patients must have, in the opinion of the Investigator, fully recovered from their prior allergic reaction to E. coli-derived asparaginase.\nHealthy volunteers allowed",
    "exclusion_criteria": "1. Have previously received asparaginase Erwinia chrysanthemi or JZP-458.\n2. Have relapsed ALL or LBL.\n3. Are concurrently receiving another investigational agent and/or treated with an investigational device at the same time as JZP-458 (within 48 hours) during Course 1 of JZP-458.\n4. Have a history of ≥ Grade 3 pancreatitis.\n5. Prior history of asparaginase-associated ≥ Grade 3 hemorrhagic event or asparaginase-associated thrombus requiring anticoagulation therapy, excluding catheter-related thrombotic events.",
    "miscellaneous_criteria": ""
}